TFG-NTRK1/BaF3
CBP73193
詢 價
留 言
產(chǎn)品描述
產(chǎn)品數(shù)據(jù)庫
| I. Introduction | |
| Cell Line Name： | TFG-NTRK1/BaF3 |
| Host Cell: | Ba/F3 |
| Stability: | 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
| Application: | Anti-proliferation assay and PD assay |
| Freeze Medium: | 90% FBS+10% DMSO |
| Complete Culture Medium: | RPMI-1640+10% FBS+1 ug/ml puromycin |
| Mycoplasma Status: | Negative |
| II. Background | |
| NTRK1 rearrangements involve the kinase domain of the NTRK1 gene which includes 17 exons located on chromosome 1q21-22 (Alberti et al. 2003). The frequency of NTRK1 fusions in patients with adenocarcinoma histology is 3.3% of cases (3 out of 91 patients; Vaishnavi et al. 2013). a In preclinical studies, cell lines expressing MPRIP-NTRK1 or CD74-NTRK1 were inhibited by ARRY-470, a TRKA/B/C inhibitor (Vaishnavi et al. 2013). b In preclinical studies, cell lines expressing MPRIP-NTRK1 or CD74-NTRK1 were inhibited by lestaurtinib, a FLT3/TRKA inhibitor (Vaishnavi et al. 2013). c A patient with non-small cell lung cancer harboring an MPRIP-NTRK1 fusion mutation was treated with crizotinib, which has activity against TRKA in addition to ALK, MET and ROS1 (Vaishnavi et al. 2013). The patient demonstrated a small radiographic decrease in tumor size but experienced disease progression after three months (Vaishnavi et al. 2013) |
|
| III. Representative Data | |
|
1. WB of TFG-NTRK1/BaF3 expression
|
|
|
2. Anti-proliferation assay |
|
|
Figure 2. Anti-proliferation assay of two reference compounds on the TFG-NTRK1/BaF3 Stable Cell Line |
|
